{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:16:58Z","timestamp":1793132218416,"version":"4.5.0"},"reference-count":187,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001773","name":"University of New South Wales","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001773","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.neuropharm.2016.03.024","type":"journal-article","created":{"date-parts":[[2016,3,16]],"date-time":"2016-03-16T22:34:28Z","timestamp":1458167668000},"page":"373-388","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":364,"special_numbering":"PB","title":["Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases"],"prefix":"10.1016","volume":"112","author":[{"given":"Michael D.","family":"Lovelace","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Varney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayathri","family":"Sundaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Lennon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chai K.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles J.","family":"Guillemin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce J.","family":"Brew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.neuropharm.2016.03.024_bib1","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1172\/JCI116518","article-title":"Quantitation of human immunodeficiency virus, immune activation factors, and quinolinic acid in AIDS brains","volume":"91","author":"Achim","year":"1993","journal-title":"J.\u00a0Clin. Investig."},{"issue":"2","key":"10.1016\/j.neuropharm.2016.03.024_bib2","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1160\/TH05-01-0053","article-title":"Role of human brain microvascular endothelial cells during central nervous system infection. Significance of indoleamine 2,3-dioxygenase in antimicrobial defence and immunoregulation","volume":"94","author":"Adam","year":"2005","journal-title":"Thromb. Haemost."},{"issue":"9","key":"10.1016\/j.neuropharm.2016.03.024_bib3","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.micinf.2004.04.007","article-title":"Inhibition of human herpes simplex virus type 2 by interferon gamma and tumor necrosis factor alpha is mediated by indoleamine 2,3-dioxygenase","volume":"6","author":"Adams","year":"2004","journal-title":"Microbes Infect."},{"key":"10.1016\/j.neuropharm.2016.03.024_bib4","first-page":"124","article-title":"Focal cerebral increases of alpha-[11C] methyl-L-tryptophan uptake suggest activation of the kynurenine pathway in multiple sclerosis: a PET study","volume":"74","author":"Alkonyi","year":"2010","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.neuropharm.2016.03.024_bib5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jri.2003.11.003","article-title":"Indoleamine 2,3-dioxygenase expression is restricted to fetal trophoblast giant cells during murine gestation and is maternal genome specific","volume":"61","author":"Baban","year":"2004","journal-title":"J.\u00a0Reprod. Immunol."},{"issue":"1","key":"10.1016\/j.neuropharm.2016.03.024_bib6","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.gene.2007.04.010","article-title":"Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice","volume":"396","author":"Ball","year":"2007","journal-title":"Gene"},{"issue":"2","key":"10.1016\/j.neuropharm.2016.03.024_bib174","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1042\/bj2680437","article-title":"Glutamine synthesis from aspartate in guinea-pig renal cortex","volume":"268","author":"Baverel","year":"1990","journal-title":"Biochem. J"},{"issue":"1","key":"10.1016\/j.neuropharm.2016.03.024_bib7","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/0022-510X(92)90191-M","article-title":"Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex","volume":"108","author":"Beal","year":"1992","journal-title":"J.\u00a0Neurol. Sci."},{"issue":"4","key":"10.1016\/j.neuropharm.2016.03.024_bib8","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1111\/j.1471-4159.1990.tb03143.x","article-title":"Kynurenine pathway measurements in Huntington's disease striatum: evidence for reduced formation of kynurenic acid","volume":"55","author":"Beal","year":"1990","journal-title":"J.\u00a0Neurochem."},{"issue":"2","key":"10.1016\/j.neuropharm.2016.03.024_bib9","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.phymed.2013.08.008","article-title":"Comparison of in\u00a0vitro tests for antioxidant and immunomodulatory capacities of compounds","volume":"21","author":"Becker","year":"2014","journal-title":"Phytomedicine"},{"issue":"7","key":"10.1016\/j.neuropharm.2016.03.024_bib10","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.4049\/jimmunol.0803314","article-title":"Combined effect of antiretroviral therapy and blockade of IDO in SIV-infected rhesus macaques","volume":"182","author":"Boasso","year":"2009","journal-title":"J.\u00a0Immunol."},{"issue":"5","key":"10.1016\/j.neuropharm.2016.03.024_bib11","doi-asserted-by":"crossref","first-page":"9772","DOI":"10.3390\/ijms16059772","article-title":"Changing the face of kynurenines and neurotoxicity: therapeutic considerations","volume":"16","author":"Bohar","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2016.03.024_bib12","first-page":"379069","article-title":"The fat-fed apolipoprotein E knockout mouse brachiocephalic artery in the study of atherosclerotic plaque rupture","volume":"2011","author":"Bond","year":"2011","journal-title":"J.\u00a0Biomed. Biotechnol."},{"issue":"4","key":"10.1016\/j.neuropharm.2016.03.024_bib13","first-page":"161","article-title":"Indoleamine 2,3-dioxygenase and 3OH-kynurenine modifications are found in the neuropathology of Alzheimer disease","volume":"15","author":"Bonda","year":"2010","journal-title":"Redox Rep. Commun. Free Radic. Res."},{"issue":"1","key":"10.1016\/j.neuropharm.2016.03.024_bib14","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s12640-009-9051-z","article-title":"Mechanism for quinolinic acid cytotoxicity in human astrocytes and neurons","volume":"16","author":"Braidy","year":"2009","journal-title":"Neurotox. Res."},{"issue":"3","key":"10.1016\/j.neuropharm.2016.03.024_bib15","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/infdis\/jiu115","article-title":"The kynurenine pathway of tryptophan catabolism, CD4+ T-cell recovery, and mortality among HIV-infected Ugandans initiating antiretroviral therapy","volume":"210","author":"Byakwaga","year":"2014","journal-title":"J.\u00a0Infect. Dis."},{"issue":"11","key":"10.1016\/j.neuropharm.2016.03.024_bib16","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.cub.2011.04.028","article-title":"The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease","volume":"21","author":"Campesan","year":"2011","journal-title":"Curr. Biol."},{"issue":"2","key":"10.1016\/j.neuropharm.2016.03.024_bib17","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.bbr.2010.02.041","article-title":"Protective effect of systemic L-kynurenine and probenecid administration on behavioural and morphological alterations induced by toxic soluble amyloid beta (25-35) in rat hippocampus","volume":"210","author":"Carrillo-Mora","year":"2010","journal-title":"Behav. Brain Res."},{"issue":"7","key":"10.1016\/j.neuropharm.2016.03.024_bib18","doi-asserted-by":"crossref","first-page":"e100446","DOI":"10.1371\/journal.pone.0100446","article-title":"Anti-retroviral therapy decreases but does not normalize indoleamine 2,3-dioxygenase activity in HIV-infected patients","volume":"9","author":"Chen","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.neuropharm.2016.03.024_bib19","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/j.1471-4159.2010.07159.x","article-title":"Characterization of the kynurenine pathway in NSC-34 cell line: implications for amyotrophic lateral sclerosis","volume":"118","author":"Chen","year":"2011","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2016.03.024_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4137\/IJTR.S2097","article-title":"Kynurenine pathway metabolites in humans: disease and healthy States","volume":"2","author":"Chen","year":"2009","journal-title":"Int. J. Tryptophan Res."},{"issue":"2","key":"10.1016\/j.neuropharm.2016.03.024_bib21","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s12640-009-9129-7","article-title":"The kynurenine pathway and inflammation in amyotrophic lateral sclerosis","volume":"18","author":"Chen","year":"2010","journal-title":"Neurotox. Res."},{"issue":"1","key":"10.1016\/j.neuropharm.2016.03.024_bib175","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2174\/187152409787601941","article-title":"Recent advances in the treatment of amyotrophic lateral sclerosis. Emphasis on kynurenine pathway inhibitors","volume":"9","author":"Chen","year":"2009","journal-title":"Cent. Nerv. Syst. Agents Med. Chem"},{"issue":"3","key":"10.1016\/j.neuropharm.2016.03.024_bib22","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0306-4522(00)00504-2","article-title":"Kynurenine 3-mono-oxygenase activity and neurotoxic kynurenine metabolites increase in the spinal cord of rats with experimental allergic encephalomyelitis","volume":"102","author":"Chiarugi","year":"2001","journal-title":"Neuroscience"},{"issue":"7","key":"10.1016\/j.neuropharm.2016.03.024_bib23","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1073\/pnas.87.7.2506","article-title":"Antioxidant activities of some tryptophan metabolites: possible implication for inflammatory diseases","volume":"87","author":"Christen","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"8","key":"10.1016\/j.neuropharm.2016.03.024_bib24","doi-asserted-by":"crossref","first-page":"5249","DOI":"10.1128\/IAI.73.8.5249-5251.2005","article-title":"Prolonged survival of a murine model of cerebral malaria by kynurenine pathway inhibition","volume":"73","author":"Clark","year":"2005","journal-title":"Infect. Immun."},{"issue":"42","key":"10.1016\/j.neuropharm.2016.03.024_bib25","doi-asserted-by":"crossref","first-page":"13033","DOI":"10.1073\/pnas.1517820112","article-title":"Indoleamine 2,3-dioxygenase-1 is protective in atherosclerosis and its metabolites provide new opportunities for drug development","volume":"112","author":"Cole","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7","key":"10.1016\/j.neuropharm.2016.03.024_bib26","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/00004647-199907000-00007","article-title":"Kynurenine hydroxylase inhibitors reduce ischemic brain damage: studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[-N-4-(nitrophenyl)thiazol-2yl]-benzenesulfonamide (Ro 61-8048) in models of focal or global brain ischemia","volume":"19","author":"Cozzi","year":"1999","journal-title":"J.\u00a0Cereb. Blood Flow Metab."},{"issue":"2","key":"10.1016\/j.neuropharm.2016.03.024_bib27","doi-asserted-by":"crossref","first-page":"e14698","DOI":"10.1371\/journal.pone.0014698","article-title":"Interferon-gamma regulates the proliferation and differentiation of mesenchymal stem cells via activation of indoleamine 2,3 dioxygenase (IDO)","volume":"6","author":"Croitoru-Lamoury","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2016.03.024_bib28","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4137\/IJTR.S4321","article-title":"Tryptophan, neurodegeneration and HIV-associated neurocognitive disorder","volume":"3","author":"Davies","year":"2010","journal-title":"Int. J. Tryptophan Res."},{"issue":"1","key":"10.1016\/j.neuropharm.2016.03.024_bib176","first-page":"18","article-title":"Timeliness of diagnosis in motor neurone disease: a population-based study","volume":"77","author":"Donaghy","year":"2008","journal-title":"Ulster Med. J"},{"issue":"11","key":"10.1016\/j.neuropharm.2016.03.024_bib29","doi-asserted-by":"crossref","first-page":"6752","DOI":"10.4049\/jimmunol.176.11.6752","article-title":"The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells","volume":"176","author":"Fallarino","year":"2006","journal-title":"J.\u00a0Immunol."},{"issue":"9","key":"10.1016\/j.neuropharm.2016.03.024_bib30","doi-asserted-by":"crossref","first-page":"5031","DOI":"10.4049\/jimmunol.151.9.5031","article-title":"Elevated IFN-gamma and decreased IL-2 gene expression are associated with HIV infection","volume":"151","author":"Fan","year":"1993","journal-title":"J.\u00a0Immunol."},{"issue":"32","key":"10.1016\/j.neuropharm.2016.03.024_bib31","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3000632","article-title":"Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease","volume":"2","author":"Favre","year":"2010","journal-title":"Sci. Transl. Med."},{"issue":"7","key":"10.1016\/j.neuropharm.2016.03.024_bib32","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1089\/jir.2014.0052","article-title":"Interferon Lambda upregulates IDO1 expression in respiratory epithelial cells after influenza virus infection","volume":"35","author":"Fox","year":"2015","journal-title":"J.\u00a0Interferon Cytokine Res."},{"issue":"Pt 7","key":"10.1016\/j.neuropharm.2016.03.024_bib33","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1099\/vir.0.053124-0","article-title":"Inhibition of indoleamine 2,3-dioxygenase enhances the T-cell response to influenza virus infection","volume":"94","author":"Fox","year":"2013","journal-title":"J.\u00a0Gen. Virol."},{"issue":"3","key":"10.1016\/j.neuropharm.2016.03.024_bib34","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1189\/jlb.3AB0114-046RR","article-title":"Drug analog inhibition of indoleamine 2,3-dioxygenase (IDO) activity modifies pattern recognition receptor expression and proinflammatory cytokine responses early during influenza virus infection","volume":"96","author":"Fox","year":"2014","journal-title":"J.\u00a0Leukoc. Biol."},{"issue":"6","key":"10.1016\/j.neuropharm.2016.03.024_bib36","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1111\/j.1471-4159.1991.tb03460.x","article-title":"Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism","volume":"56","author":"Fukui","year":"1991","journal-title":"J.\u00a0Neurochem."},{"issue":"2","key":"10.1016\/j.neuropharm.2016.03.024_bib177","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00702-012-0765-3","article-title":"The role of kynurenines in the pathomechanism of amyotrophic lateral sclerosis and multiple sclerosis: therapeutic implications","volume":"119","author":"F\u00fcvesi","year":"2012","journal-title":"J. Neural. Transm. (Vienna)"},{"key":"10.1016\/j.neuropharm.2016.03.024_bib37","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.neuroscience.2013.04.063","article-title":"Post-ischemic treatment with L-kynurenine sulfate exacerbates neuronal damage after transient middle cerebral artery occlusion","volume":"247","author":"Gellert","year":"2013","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2016.03.024_bib38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/7854_2013_238","article-title":"Clinical aspects of Huntington's disease","volume":"22","author":"Ghosh","year":"2015","journal-title":"Curr. Top. Behav. Neurosci."},{"issue":"1\u20133","key":"10.1016\/j.neuropharm.2016.03.024_bib39","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejphar.2007.02.029","article-title":"Neuroprotective effect of L-kynurenine sulfate administered before focal cerebral ischemia in mice and global cerebral ischemia in gerbils","volume":"564","author":"Gigler","year":"2007","journal-title":"Eur. J. Pharmacol."},{"issue":"9","key":"10.1016\/j.neuropharm.2016.03.024_bib40","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1128\/JVI.74.9.4110-4115.2000","article-title":"Induction of indolamine 2,3-dioxygenase in primary human macrophages by human immunodeficiency virus type 1 is strain dependent","volume":"74","author":"Grant","year":"2000","journal-title":"J.\u00a0Virol."},{"issue":"2","key":"10.1016\/j.neuropharm.2016.03.024_bib41","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.bbr.2007.08.007","article-title":"Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys","volume":"186","author":"Gregoire","year":"2008","journal-title":"Behav. Brain Res."},{"issue":"1","key":"10.1016\/j.neuropharm.2016.03.024_bib42","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.nbd.2006.02.011","article-title":"Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice","volume":"23","author":"Guidetti","year":"2006","journal-title":"Neurobiol. Dis."},{"issue":"3","key":"10.1016\/j.neuropharm.2016.03.024_bib43","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.nbd.2004.07.006","article-title":"Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease","volume":"17","author":"Guidetti","year":"2004","journal-title":"Neurobiol. Dis."},{"issue":"8","key":"10.1016\/j.neuropharm.2016.03.024_bib44","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1111\/j.1742-4658.2012.08485.x","article-title":"Quinolinic acid, the inescapable neurotoxin","volume":"279","author":"Guillemin","year":"2012","journal-title":"FEBS J."},{"issue":"4","key":"10.1016\/j.neuropharm.2016.03.024_bib45","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1365-2990.2005.00655.x","article-title":"Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer's disease hippocampus","volume":"31","author":"Guillemin","year":"2005","journal-title":"Neuropathol. Appl. Neurobiol."},{"issue":"4","key":"10.1016\/j.neuropharm.2016.03.024_bib46","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/glia.10175","article-title":"Quinolinic acid upregulates chemokine production and chemokine receptor expression in astrocytes","volume":"41","author":"Guillemin","year":"2003","journal-title":"GLIA"},{"issue":"47","key":"10.1016\/j.neuropharm.2016.03.024_bib47","doi-asserted-by":"crossref","first-page":"12884","DOI":"10.1523\/JNEUROSCI.4101-07.2007","article-title":"Characterization of the kynurenine pathway in human neurons","volume":"27","author":"Guillemin","year":"2007","journal-title":"J.\u00a0Neurosci."},{"issue":"4","key":"10.1016\/j.neuropharm.2016.03.024_bib48","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1046\/j.1471-4159.2001.00498.x","article-title":"Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection","volume":"78","author":"Guillemin","year":"2001","journal-title":"J.\u00a0Neurochem."},{"issue":"1","key":"10.1016\/j.neuropharm.2016.03.024_bib49","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/glia.20090","article-title":"Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons","volume":"49","author":"Guillemin","year":"2005","journal-title":"GLIA"},{"issue":"18","key":"10.1016\/j.neuropharm.2016.03.024_bib50","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1097\/00001756-200312190-00005","article-title":"A\u00a0beta 1-42 induces production of quinolinic acid by human macrophages and microglia","volume":"14","author":"Guillemin","year":"2003","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2016.03.024_bib51","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/978-1-4615-0135-0_19","article-title":"Quinolinic acid in the pathogenesis of Alzheimer's disease","volume":"527","author":"Guillemin","year":"2003","journal-title":"Adv. Exp. Med. Biol."},{"issue":"2","key":"10.1016\/j.neuropharm.2016.03.024_bib52","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1600-0404.2005.00442.x","article-title":"Kynurenine metabolism in multiple sclerosis","volume":"112","author":"Hartai","year":"2005","journal-title":"Acta Neurol. Scand."},{"issue":"1","key":"10.1016\/j.neuropharm.2016.03.024_bib53","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jns.2005.07.006","article-title":"Kynurenine metabolism in plasma and in red blood cells in Parkinson's disease","volume":"239","author":"Hartai","year":"2005","journal-title":"J.\u00a0Neurol. Sci."},{"issue":"2","key":"10.1016\/j.neuropharm.2016.03.024_bib54","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/ana.410290215","article-title":"Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status","volume":"29","author":"Heyes","year":"1991","journal-title":"Ann. Neurol."},{"issue":"Pt 5","key":"10.1016\/j.neuropharm.2016.03.024_bib55","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1093\/brain\/124.5.1033","article-title":"Elevated cerebrospinal fluid quinolinic acid levels are associated with region-specific cerebral volume loss in HIV infection","volume":"124","author":"Heyes","year":"2001","journal-title":"Brain"},{"issue":"1\u20132","key":"10.1016\/j.neuropharm.2016.03.024_bib56","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0006-8993(92)90587-Y","article-title":"Relationship of neurologic status in macaques infected with the simian immunodeficiency virus to cerebrospinal fluid quinolinic acid and kynurenic acid","volume":"570","author":"Heyes","year":"1992","journal-title":"Brain Res."},{"issue":"Pt 5","key":"10.1016\/j.neuropharm.2016.03.024_bib57","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1093\/brain\/115.5.1249","article-title":"Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease","volume":"115","author":"Heyes","year":"1992","journal-title":"Brain"},{"issue":"19","key":"10.1016\/j.neuropharm.2016.03.024_bib58","doi-asserted-by":"crossref","first-page":"7463","DOI":"10.1523\/JNEUROSCI.21-19-07463.2001","article-title":"The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications","volume":"21","author":"Hilmas","year":"2001","journal-title":"J.\u00a0Neurosci."},{"issue":"11","key":"10.1016\/j.neuropharm.2016.03.024_bib59","doi-asserted-by":"crossref","first-page":"4487","DOI":"10.1128\/IAI.02113-14","article-title":"Blockade of indoleamine 2,3-dioxygenase reduces mortality from peritonitis and sepsis in mice by regulating functions of CD11b+ peritoneal cells","volume":"82","author":"Hoshi","year":"2014","journal-title":"Infect. Immun."},{"issue":"2","key":"10.1016\/j.neuropharm.2016.03.024_bib60","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3109\/08830180903349669","article-title":"Dendritic cells, indoleamine 2,3 dioxygenase and acquired immune privilege","volume":"29","author":"Huang","year":"2010","journal-title":"Int. Rev. Immunol."},{"issue":"11","key":"10.1016\/j.neuropharm.2016.03.024_bib61","doi-asserted-by":"crossref","first-page":"4425","DOI":"10.1128\/IAI.05659-11","article-title":"Inhibition of indoleamine 2,3-dioxygenase activity by levo-1-methyl tryptophan blocks gamma interferon-induced Chlamydia trachomatis persistence in human epithelial cells","volume":"79","author":"Ibana","year":"2011","journal-title":"Infect. Immun."},{"issue":"6","key":"10.1016\/j.neuropharm.2016.03.024_bib178","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1034\/j.1600-0404.2003.00076.x","article-title":"Endogenous protectant kynurenic acid in amyotrophic lateral sclerosis","volume":"107","author":"I\u0142zecka","year":"2003","journal-title":"Acta Neurol. Scand"},{"issue":"9","key":"10.1016\/j.neuropharm.2016.03.024_bib62","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1093\/rheumatology\/kem160","article-title":"The anti-allergic drug, N-(3',4'-dimethoxycinnamonyl) anthranilic acid, exhibits potent anti-inflammatory and analgesic properties in arthritis","volume":"46","author":"Inglis","year":"2007","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.neuropharm.2016.03.024_bib63","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/nrd1901","article-title":"Anti-inflammatory effects of statins: clinical evidence and basic mechanisms","volume":"4","author":"Jain","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.neuropharm.2016.03.024_bib64","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s12640-015-9535-y","article-title":"Protective effect of Spermidine against excitotoxic neuronal death induced by quinolinic acid in rats: possible neurotransmitters and neuroinflammatory mechanism","volume":"28","author":"Jamwal","year":"2015","journal-title":"Neurotox. Res."},{"issue":"1","key":"10.1016\/j.neuropharm.2016.03.024_bib65","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0022-510X(94)00280-2","article-title":"Dysfunction of brain kynurenic acid metabolism in Huntington's disease: focus on kynurenine aminotransferases","volume":"130","author":"Jauch","year":"1995","journal-title":"J.\u00a0Neurol. Sci."},{"issue":"10","key":"10.1016\/j.neuropharm.2016.03.024_bib66","doi-asserted-by":"crossref","first-page":"e78146","DOI":"10.1371\/journal.pone.0078146","article-title":"Distinct tryptophan catabolism and Th17\/Treg balance in HIV progressors and elite controllers","volume":"8","author":"Jenabian","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.neuropharm.2016.03.024_bib179","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.fct.2007.07.017","article-title":"Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: absence of toxicity due to saturating absorption","volume":"46","author":"Jia","year":"2008","journal-title":"Food Chem Toxicol"},{"issue":"6","key":"10.1016\/j.neuropharm.2016.03.024_bib67","doi-asserted-by":"crossref","first-page":"e0131389","DOI":"10.1371\/journal.pone.0131389","article-title":"Expression of the kynurenine pathway in human peripheral blood mononuclear cells: implications for inflammatory and neurodegenerative disease","volume":"10","author":"Jones","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2016.03.024_bib68","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4137\/IJTR.S12626","article-title":"The kynurenine pathway in stem cell biology","volume":"6","author":"Jones","year":"2013","journal-title":"Int. J. Tryptophan Res."},{"issue":"8","key":"10.1016\/j.neuropharm.2016.03.024_bib69","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1111\/j.1742-4658.2012.08500.x","article-title":"The kynurenine pathway and quinolinic acid: pivotal roles in HIV associated neurocognitive disorders","volume":"279","author":"Kandanearatchi","year":"2012","journal-title":"FEBS J."},{"key":"10.1016\/j.neuropharm.2016.03.024_bib70","article-title":"Associations between intake of fish and n-3 long-chain polyunsaturated fatty acids and plasma metabolites related to the kynurenine pathway in patients with coronary artery disease","author":"Karlsson","year":"2015","journal-title":"Eur. J. Nutr."},{"issue":"3","key":"10.1016\/j.neuropharm.2016.03.024_bib71","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000086295","article-title":"Age-related increase of kynurenic acid in human cerebrospinal fluid \u2013 IgG and beta2-microglobulin changes","volume":"14","author":"Kepplinger","year":"2005","journal-title":"Neurosignals"},{"issue":"4","key":"10.1016\/j.neuropharm.2016.03.024_bib72","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/00002030-199804000-00003","article-title":"Chronic exposure of human neurons to quinolinic acid results in neuronal changes consistent with AIDS dementia complex","volume":"12","author":"Kerr","year":"1998","journal-title":"AIDS"},{"issue":"6","key":"10.1016\/j.neuropharm.2016.03.024_bib73","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1212\/WNL.49.6.1671","article-title":"Kynurenine pathway inhibition reduces neurotoxicity of HIV-1-infected macrophages","volume":"49","author":"Kerr","year":"1997","journal-title":"Neurology"},{"issue":"9769","key":"10.1016\/j.neuropharm.2016.03.024_bib180","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/S0140-6736(10)61156-7","article-title":"Amyotrophic lateral sclerosis","volume":"377","author":"Kiernan","year":"2011","journal-title":"Lancet"},{"issue":"2\u20133","key":"10.1016\/j.neuropharm.2016.03.024_bib74","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jad.2004.12.013","article-title":"Measurement of tryptophan, kynurenine and neopterin in women with and without postpartum blues","volume":"86","author":"Kohl","year":"2005","journal-title":"J.\u00a0Affect Disord."},{"issue":"12","key":"10.1016\/j.neuropharm.2016.03.024_bib75","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1007\/s00109-007-0229-7","article-title":"IDO expression in the brain: a double-edged sword","volume":"85","author":"Kwidzinski","year":"2007","journal-title":"J.\u00a0Mol. Med. (Berl.)"},{"issue":"10","key":"10.1016\/j.neuropharm.2016.03.024_bib76","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1096\/fj.04-3228fje","article-title":"Indolamine 2,3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation","volume":"19","author":"Kwidzinski","year":"2005","journal-title":"FASEB J."},{"issue":"10","key":"10.1016\/j.neuropharm.2016.03.024_bib77","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1515\/CCLM.1998.132","article-title":"Activated immune system in patients with Huntington's disease","volume":"36","author":"Leblhuber","year":"1998","journal-title":"Clin. Chem. Lab. Med."},{"issue":"11","key":"10.1016\/j.neuropharm.2016.03.024_bib78","doi-asserted-by":"crossref","first-page":"e14123","DOI":"10.1371\/journal.pone.0014123","article-title":"Characterisation of the expression of NMDA receptors in human astrocytes","volume":"5","author":"Lee","year":"2010","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.neuropharm.2016.03.024_bib79","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.neuint.2006.04.017","article-title":"In\u00a0vitro evidence for an antioxidant role of 3-hydroxykynurenine and 3-hydroxyanthranilic acid in the brain","volume":"50","author":"Leipnitz","year":"2007","journal-title":"Neurochem. Int."},{"issue":"1\u20132","key":"10.1016\/j.neuropharm.2016.03.024_bib80","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.cell.2014.12.028","article-title":"Kynurenic acid is a nutritional cue that enables behavioral plasticity","volume":"160","author":"Lemieux","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2016.03.024_bib81","doi-asserted-by":"crossref","first-page":"157","DOI":"10.4137\/IJTR.S4294","article-title":"Understanding the roles of the kynurenine pathway in multiple sclerosis progression","volume":"3","author":"Lim","year":"2010","journal-title":"Int. J. Tryptophan Res."},{"key":"10.1016\/j.neuropharm.2016.03.024_bib82","article-title":"Involvement of the kynurenine pathway in the pathogenesis of Parkinson's disease","author":"Lim","year":"2016","journal-title":"Prog. Neurobiol"},{"issue":"5","key":"10.1016\/j.neuropharm.2016.03.024_bib83","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1158\/0008-5472.CAN-13-1656","article-title":"Mesenchymal stem cells use IDO to regulate immunity in tumor microenvironment","volume":"74","author":"Ling","year":"2014","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.neuropharm.2016.03.024_bib84","doi-asserted-by":"crossref","first-page":"e0130715","DOI":"10.1371\/journal.pone.0130715","article-title":"Indoleamine 2,3 dioxygenase (IDO) expression and activity in relapsing-remitting multiple sclerosis","volume":"10","author":"Mancuso","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.neuropharm.2016.03.024_bib85","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00702-011-0681-y","article-title":"The kynurenine system and immunoregulation","volume":"119","author":"Mandi","year":"2012","journal-title":"J.\u00a0Neural Transm. (Vienna)"},{"key":"10.1016\/j.neuropharm.2016.03.024_bib86","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1742-4933-8-9","article-title":"Aging-associated increase in indoleamine 2,3-dioxygenase (IDO) activity appears to be unrelated to the transcription of the IDO1 or IDO2 genes in peripheral blood mononuclear cells","volume":"8","author":"Marttila","year":"2011","journal-title":"Immun. Ageing"},{"issue":"1","key":"10.1016\/j.neuropharm.2016.03.024_bib87","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/nri2233","article-title":"Creating immune privilege: active local suppression that benefits friends, but protects foes","volume":"8","author":"Mellor","year":"2008","journal-title":"Nat. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.neuropharm.2016.03.024_bib88","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.cmet.2015.07.004","article-title":"Indoleamine 2,3-Dioxygenase Fine-Tunes immune homeostasis in atherosclerosis and Colitis through repression of Interleukin-10 production","volume":"22","author":"Metghalchi","year":"2015","journal-title":"Cell Metab."},{"issue":"3","key":"10.1016\/j.neuropharm.2016.03.024_bib89","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.nbd.2003.12.015","article-title":"Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia","volume":"15","author":"Miller","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2016.03.024_bib188","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(07)60944-1","article-title":"Amyotrophic lateral sclerosis","volume":"369","author":"Mitchell","year":"2007","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.neuropharm.2016.03.024_bib90","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1136\/jnnp.42.7.640","article-title":"Plasma and cerebrospinal fluid tryptophan in multiple sclerosis and degenerative diseases","volume":"42","author":"Monaco","year":"1979","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neuropharm.2016.03.024_bib91","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s40425-015-0094-9","article-title":"Targeting the indoleamine 2,3-dioxygenase pathway in cancer","volume":"3","author":"Moon","year":"2015","journal-title":"J.\u00a0Immunother. Cancer"},{"issue":"6","key":"10.1016\/j.neuropharm.2016.03.024_bib92","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.pneurobio.2004.10.004","article-title":"Structure and function of amyloid in Alzheimer's disease","volume":"74","author":"Morgan","year":"2004","journal-title":"Prog. Neurobiol."},{"issue":"1\u20133","key":"10.1016\/j.neuropharm.2016.03.024_bib93","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0014-2999(99)00196-X","article-title":"Tryptophan metabolism and brain function: focus on kynurenine and other indole metabolites","volume":"375","author":"Moroni","year":"1999","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.neuropharm.2016.03.024_bib94","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/nm1196","article-title":"Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy","volume":"11","author":"Muller","year":"2005","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.neuropharm.2016.03.024_bib95","doi-asserted-by":"crossref","first-page":"R1159","DOI":"10.1152\/ajpregu.00767.2006","article-title":"Denervation-induced skeletal muscle atrophy is associated with increased mitochondrial ROS production","volume":"293","author":"Muller","year":"2007","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"issue":"9","key":"10.1016\/j.neuropharm.2016.03.024_bib96","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1084\/jem.189.9.1363","article-title":"Inhibition of T cell proliferation by macrophage tryptophan catabolism","volume":"189","author":"Munn","year":"1999","journal-title":"J.\u00a0Exp. Med."},{"issue":"5","key":"10.1016\/j.neuropharm.2016.03.024_bib97","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.immuni.2005.03.013","article-title":"GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase","volume":"22","author":"Munn","year":"2005","journal-title":"Immunity"},{"issue":"5380","key":"10.1016\/j.neuropharm.2016.03.024_bib98","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1126\/science.281.5380.1191","article-title":"Prevention of allogeneic fetal rejection by tryptophan catabolism","volume":"281","author":"Munn","year":"1998","journal-title":"Science"},{"issue":"42","key":"10.1016\/j.neuropharm.2016.03.024_bib99","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1093\/eurheartj\/ehu299","article-title":"Cardiovascular disease in Europe 2014: epidemiological update","volume":"35","author":"Nichols","year":"2014","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.neuropharm.2016.03.024_bib100","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/ni1328","article-title":"See no evil, hear no evil, do no evil: the lessons of immune privilege","volume":"7","author":"Niederkorn","year":"2006","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.neuropharm.2016.03.024_bib101","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/07853890903321559","article-title":"Activation of indoleamine 2,3-dioxygenase-induced tryptophan degradation in advanced atherosclerotic plaques: Tampere vascular study","volume":"42","author":"Niinisalo","year":"2010","journal-title":"Ann. Med."},{"issue":"8","key":"10.1016\/j.neuropharm.2016.03.024_bib102","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1080\/00365510802245685","article-title":"Indoleamine 2,3-dioxygenase activity associates with cardiovascular risk factors: the Health 2000 study","volume":"68","author":"Niinisalo","year":"2008","journal-title":"Scand. J. Clin. Lab. Investig."},{"issue":"22","key":"10.1016\/j.neuropharm.2016.03.024_bib181","doi-asserted-by":"crossref","first-page":"12553","DOI":"10.1073\/pnas.93.22.12553","article-title":"Hydrogen peroxide-mediated neuronal cell death induced by an endogenous neurotoxin, 3-hydroxykynurenine","volume":"93","author":"Okuda","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"issue":"1","key":"10.1016\/j.neuropharm.2016.03.024_bib182","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1046\/j.1471-4159.1998.70010299.x","article-title":"3-Hydroxykynurenine, an endogenous oxidative stress generator, causes neuronal cell death with apoptotic features and region selectivity","volume":"70","author":"Okuda","year":"1998","journal-title":"J. Neurochem"},{"issue":"4","key":"10.1016\/j.neuropharm.2016.03.024_bib103","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1111\/j.1471-4159.2008.05241.x","article-title":"Kynurenine pathway metabolism in human blood-brain-barrier cells: implications for immune tolerance and neurotoxicity","volume":"105","author":"Owe-Young","year":"2008","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2016.03.024_bib104","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1196\/annals.1403.003","article-title":"Genetic and hormonal regulation of tryptophan kynurenine metabolism: implications for vascular cognitive impairment, major depressive disorder, and aging","volume":"1122","author":"Oxenkrug","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"1","key":"10.1016\/j.neuropharm.2016.03.024_bib105","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00702-010-0475-7","article-title":"Interferon-gamma-inducible kynurenines\/pteridines inflammation cascade: implications for aging and aging-associated psychiatric and medical disorders","volume":"118","author":"Oxenkrug","year":"2011","journal-title":"J.\u00a0Neural Transm. (Vienna)"},{"issue":"1\u20132","key":"10.1016\/j.neuropharm.2016.03.024_bib106","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0304-3940(92)90749-W","article-title":"Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington's disease","volume":"144","author":"Pearson","year":"1992","journal-title":"Neurosci. Lett."},{"issue":"3","key":"10.1016\/j.neuropharm.2016.03.024_bib107","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1161\/ATVBAHA.110.219329","article-title":"Systemic markers of interferon-gamma-mediated immune activation and long-term prognosis in patients with stable coronary artery disease","volume":"31","author":"Pedersen","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"34","key":"10.1016\/j.neuropharm.2016.03.024_bib108","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1093\/eurheartj\/eht264","article-title":"Urinary excretion of kynurenine and tryptophan, cardiovascular events, and mortality after elective coronary angiography","volume":"34","author":"Pedersen","year":"2013","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.neuropharm.2016.03.024_bib109","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1161\/ATVBAHA.114.304674","article-title":"Associations of plasma kynurenines with risk of acute myocardial infarction in patients with stable angina pectoris","volume":"35","author":"Pedersen","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"10","key":"10.1016\/j.neuropharm.2016.03.024_bib110","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/jir.1997.17.589","article-title":"Quinolinic acid production by macrophages stimulated with IFN-gamma, TNF-alpha, and IFN-alpha","volume":"17","author":"Pemberton","year":"1997","journal-title":"J.\u00a0Interferon Cytokine Res."},{"issue":"1","key":"10.1016\/j.neuropharm.2016.03.024_bib111","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1365-2249.2007.03325.x","article-title":"Indoleamine 2,3-dioxygenase enzyme activity correlates with risk factors for atherosclerosis: the Cardiovascular Risk in Young Finns Study","volume":"148","author":"Pertovaara","year":"2007","journal-title":"Clin. Exp. Immunol."},{"issue":"1","key":"10.1016\/j.neuropharm.2016.03.024_bib112","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.expneurol.2010.03.009","article-title":"Acute intrastriatal administration of quinolinic acid provokes hyperphosphorylation of cytoskeletal intermediate filament proteins in astrocytes and neurons of rats","volume":"224","author":"Pierozan","year":"2010","journal-title":"Exp. Neurol."},{"issue":"5749","key":"10.1016\/j.neuropharm.2016.03.024_bib113","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1117634","article-title":"Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite","volume":"310","author":"Platten","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2016.03.024_bib114","first-page":"673","article-title":"Cancer immunotherapy by targeting IDO1\/TDO and their downstream effectors","volume":"5","author":"Platten","year":"2014","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.neuropharm.2016.03.024_bib115","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/cvr\/cvv100","article-title":"Inhibition of indoleamine 2,3-dioxygenase promotes vascular inflammation and increases atherosclerosis in Apoe-\/- mice","volume":"106","author":"Polyzos","year":"2015","journal-title":"Cardiovasc Res."},{"issue":"7","key":"10.1016\/j.neuropharm.2016.03.024_bib116","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1182\/blood-2005-04-1403","article-title":"Inhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis","volume":"106","author":"Potula","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.neuropharm.2016.03.024_bib117","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3389\/fimmu.2014.00585","article-title":"IDO2 in immunomodulation and autoimmune disease","volume":"5","author":"Prendergast","year":"2014","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.neuropharm.2016.03.024_bib118","doi-asserted-by":"crossref","first-page":"e6344","DOI":"10.1371\/journal.pone.0006344","article-title":"The excitotoxin quinolinic acid induces tau phosphorylation in human neurons","volume":"4","author":"Rahman","year":"2009","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.neuropharm.2016.03.024_bib119","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0304-3940(02)00710-3","article-title":"Decreased level of kynurenic acid in cerebrospinal fluid of relapsing-onset multiple sclerosis patients","volume":"331","author":"Rejdak","year":"2002","journal-title":"Neurosci. Lett."},{"issue":"6","key":"10.1016\/j.neuropharm.2016.03.024_bib120","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1111\/j.1471-4159.1988.tb02503.x","article-title":"Brain quinolinic acid in Huntington's disease","volume":"50","author":"Reynolds","year":"1988","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2016.03.024_bib121","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2217\/14796708.3.2.169","article-title":"L-kynurenine: metabolism and mechanism of neuroprotection","volume":"3","author":"Robotka","year":"2008","journal-title":"Future Neurol."},{"issue":"Pt 5","key":"10.1016\/j.neuropharm.2016.03.024_bib122","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1093\/brain\/awp074","article-title":"Kynurenine pathway inhibition reduces central nervous system inflammation in a model of human African trypanosomiasis","volume":"132","author":"Rodgers","year":"2009","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.neuropharm.2016.03.024_bib123","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","article-title":"Huntington's disease: from molecular pathogenesis to clinical treatment","volume":"10","author":"Ross","year":"2011","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2016.03.024_bib124","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/978-1-4613-0381-7_30","article-title":"Serum tryptophan, kynurenine, and neopterin in patients with Guillain-Barre-syndrome (GBS) and multiple sclerosis (MS)","volume":"398","author":"Rudzite","year":"1996","journal-title":"Adv. Exp. Med. Biol."},{"issue":"3","key":"10.1016\/j.neuropharm.2016.03.024_bib125","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1089\/vim.2013.0105","article-title":"Indoleamine 2,3-dioxygenase (IDO) activity during the primary immune response to influenza infection modifies the memory T cell response to influenza challenge","volume":"27","author":"Sage","year":"2014","journal-title":"Viral Immunol."},{"issue":"1","key":"10.1016\/j.neuropharm.2016.03.024_bib126","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jphs.2015.07.042","article-title":"Kynurenine causes vasodilation and hypotension induced by activation of KCNQ-encoded voltage-dependent K channels","volume":"129","author":"Sakakibara","year":"2015","journal-title":"J.\u00a0Pharmacol. Sci."},{"issue":"1\u20132","key":"10.1016\/j.neuropharm.2016.03.024_bib127","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0165-5728(02)00176-5","article-title":"Effect of indoleamine 2,3-dioxygenase on induction of experimental autoimmune encephalomyelitis","volume":"129","author":"Sakurai","year":"2002","journal-title":"J.\u00a0Neuroimmunol."},{"issue":"1","key":"10.1016\/j.neuropharm.2016.03.024_bib128","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0304-3940(95)11324-P","article-title":"Frontal cortex indoleamine-2,3-dioxygenase activity is increased in HIV-1-associated dementia","volume":"187","author":"Sardar","year":"1995","journal-title":"Neurosci. Lett."},{"issue":"1\u20132","key":"10.1016\/j.neuropharm.2016.03.024_bib129","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jns.2007.01.033","article-title":"Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders","volume":"257","author":"Sas","year":"2007","journal-title":"J.\u00a0Neurol. Sci."},{"issue":"6","key":"10.1016\/j.neuropharm.2016.03.024_bib130","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1111\/j.1471-4159.2010.06675.x","article-title":"Dysfunctional kynurenine pathway metabolism in the R6\/2 mouse model of Huntington's disease","volume":"113","author":"Sathyasaikumar","year":"2010","journal-title":"J.\u00a0Neurochem."},{"issue":"3","key":"10.1016\/j.neuropharm.2016.03.024_bib131","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/pros.21056","article-title":"Tranilast suppresses prostate cancer growth and osteoclast differentiation in\u00a0vivo and in\u00a0vitro","volume":"70","author":"Sato","year":"2010","journal-title":"Prostate"},{"issue":"2","key":"10.1016\/j.neuropharm.2016.03.024_bib132","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/npp.2014.194","article-title":"Putative neuroprotective and neurotoxic kynurenine pathway metabolites are associated with hippocampal and amygdalar volumes in subjects with major depressive disorder","volume":"40","author":"Savitz","year":"2015","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"10.1016\/j.neuropharm.2016.03.024_bib133","doi-asserted-by":"crossref","first-page":"5041","DOI":"10.4049\/jimmunol.179.8.5041","article-title":"The countervailing actions of myeloid and plasmacytoid dendritic cells control autoimmune diabetes in the nonobese diabetic mouse","volume":"179","author":"Saxena","year":"2007","journal-title":"J.\u00a0Immunol."},{"issue":"1\u20132","key":"10.1016\/j.neuropharm.2016.03.024_bib134","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.cca.2005.06.013","article-title":"Monitoring tryptophan metabolism in chronic immune activation","volume":"364","author":"Schrocksnadel","year":"2006","journal-title":"Clin. Chim. Acta"},{"issue":"1","key":"10.1016\/j.neuropharm.2016.03.024_bib135","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.coph.2003.10.006","article-title":"The kynurenine pathway of tryptophan degradation as a drug target","volume":"4","author":"Schwarcz","year":"2004","journal-title":"Curr. Opin. Pharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2016.03.024_bib136","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.pneurobio.2009.04.005","article-title":"Of mice, rats and men: revisiting the quinolinic acid hypothesis of Huntington's disease","volume":"90","author":"Schwarcz","year":"2010","journal-title":"Prog. Neurobiol."},{"issue":"4582","key":"10.1016\/j.neuropharm.2016.03.024_bib137","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1126\/science.6849138","article-title":"Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain","volume":"219","author":"Schwarcz","year":"1983","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.neuropharm.2016.03.024_bib138","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00406-012-0384-x","article-title":"Increased 3-Hydroxykynurenine serum concentrations differentiate Alzheimer's disease patients from controls","volume":"263","author":"Schwarz","year":"2013","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"9","key":"10.1016\/j.neuropharm.2016.03.024_bib139","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1172\/JCI31911","article-title":"Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase","volume":"117","author":"Sharma","year":"2007","journal-title":"J.\u00a0Clin. Investig."},{"issue":"13","key":"10.1016\/j.neuropharm.2016.03.024_bib140","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1016\/S0021-9258(17)30447-7","article-title":"Indoleamine 2,3-dioxygenase. purification and some properties","volume":"253","author":"Shimizu","year":"1978","journal-title":"J.\u00a0Biol. Chem."},{"issue":"4","key":"10.1016\/j.neuropharm.2016.03.024_bib141","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0165-6147(00)01451-6","article-title":"Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection","volume":"21","author":"Stone","year":"2000","journal-title":"Trends Pharmacol. Sci."},{"issue":"8","key":"10.1016\/j.neuropharm.2016.03.024_bib142","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nrd870","article-title":"Endogenous kynurenines as targets for drug discovery and development","volume":"1","author":"Stone","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.neuropharm.2016.03.024_bib143","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/0014-2999(81)90587-2","article-title":"Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS","volume":"72","author":"Stone","year":"1981","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.neuropharm.2016.03.024_bib144","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1471-4159.2005.03070.x","article-title":"Tryptophan metabolism and oxidative stress in patients with Huntington's disease","volume":"93","author":"Stoy","year":"2005","journal-title":"J.\u00a0Neurochem."},{"issue":"4","key":"10.1016\/j.neuropharm.2016.03.024_bib145","first-page":"835","article-title":"B\u00a0regulatory cells are increased in hypercholesterolaemic mice and protect from lesion development via IL-10","volume":"114","author":"Strom","year":"2015","journal-title":"Thromb. Haemost."},{"issue":"7","key":"10.1016\/j.neuropharm.2016.03.024_bib146","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrn3275","article-title":"Will the real multiple sclerosis please stand up?","volume":"13","author":"Stys","year":"2012","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2016.03.024_bib147","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s12974-014-0204-5","article-title":"Quinolinic acid toxicity on oligodendroglial cells: relevance for multiple sclerosis and therapeutic strategies","volume":"11","author":"Sundaram","year":"2014","journal-title":"J.\u00a0Neuroinflammation"},{"key":"10.1016\/j.neuropharm.2016.03.024_bib183","unstructured":"Sundaram, G., Lim, C.K., Guillemin, G.J., Brew, B.J., Kynurenine Pathway Activation during Experimental Autoimmune Encephalitis Disease Progression, submitted."},{"issue":"9","key":"10.1016\/j.neuropharm.2016.03.024_bib148","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1523\/JNEUROSCI.10-09-02965.1990","article-title":"Cerebral synthesis and release of kynurenic acid: an endogenous antagonist of excitatory amino acid receptors","volume":"10","author":"Swartz","year":"1990","journal-title":"J.\u00a0Neurosci."},{"issue":"16","key":"10.1016\/j.neuropharm.2016.03.024_bib149","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1161\/CIRCULATIONAHA.106.676890","article-title":"Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications","volume":"116","author":"Tabas","year":"2007","journal-title":"Circulation"},{"issue":"1-2","key":"10.1016\/j.neuropharm.2016.03.024_bib184","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jns.2012.08.005","article-title":"The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations","volume":"323","author":"Tan","year":"2012","journal-title":"J. Neurol. Sci"},{"issue":"7","key":"10.1016\/j.neuropharm.2016.03.024_bib185","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0197-0186(01)00133-4","article-title":"Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes","volume":"40","author":"Tavares","year":"2002","journal-title":"Neurochem. Int"},{"key":"10.1016\/j.neuropharm.2016.03.024_bib150","doi-asserted-by":"crossref","unstructured":"Ting, K.K., Brew B.J., Guillemin, G.J., 2007. Effect of quinolinic acid on gene expression in human astrocytes: implications for Alzheimer's disease. K. Takai. 1304, 384\u2013388.","DOI":"10.1016\/j.ics.2007.07.010"},{"issue":"3","key":"10.1016\/j.neuropharm.2016.03.024_bib151","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1046\/j.1365-2990.1999.00182.x","article-title":"REVIEW: tau protein pathology in Alzheimer's disease and related disorders","volume":"25","author":"Tolnay","year":"1999","journal-title":"Neuropathol. Appl. Neurobiol."},{"issue":"10","key":"10.1016\/j.neuropharm.2016.03.024_bib152","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/nm934","article-title":"Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase","volume":"9","author":"Uyttenhove","year":"2003","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.neuropharm.2016.03.024_bib153","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/infdis\/jiu206","article-title":"Tumor necrosis factor alpha is associated with viral control and early disease progression in patients with HIV type 1 infection","volume":"210","author":"Vaidya","year":"2014","journal-title":"J.\u00a0Infect. Dis."},{"issue":"Pt 5","key":"10.1016\/j.neuropharm.2016.03.024_bib154","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1093\/brain\/awh130","article-title":"CSF quinolinic acid levels are determined by local HIV infection: cross-sectional analysis and modelling of dynamics following antiretroviral therapy","volume":"127","author":"Valle","year":"2004","journal-title":"Brain"},{"issue":"1\u20132","key":"10.1016\/j.neuropharm.2016.03.024_bib155","first-page":"70","article-title":"Nature reviews drug discovery: editorial article of neuroscientists from Szeged about kynurenine (IF: 33.078)","volume":"67","author":"Vecsei","year":"2014","journal-title":"Ideggyogy Sz."},{"issue":"12","key":"10.1016\/j.neuropharm.2016.03.024_bib156","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/0006-3223(95)00377-0","article-title":"Huntington's disease, behavioral disturbances, and kynurenines: preclinical findings and therapeutic perspectives","volume":"39","author":"Vecsei","year":"1996","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.neuropharm.2016.03.024_bib157","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0361-9230(92)90184-Y","article-title":"Kynurenine and probenecid inhibit pentylenetetrazol- and NMDLA-induced seizures and increase kynurenic acid concentrations in the brain","volume":"28","author":"Vecsei","year":"1992","journal-title":"Brain Res. Bull."},{"issue":"1","key":"10.1016\/j.neuropharm.2016.03.024_bib158","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nrd3793","article-title":"Kynurenines in the CNS: recent advances and new questions","volume":"12","author":"Vecsei","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.neuropharm.2016.03.024_bib159","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nm.2092","article-title":"Kynurenine is an endothelium-derived relaxing factor produced during inflammation","volume":"16","author":"Wang","year":"2010","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.neuropharm.2016.03.024_bib160","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/0167-4889(89)90087-6","article-title":"Characteristics of interferon induced tryptophan metabolism in human cells in\u00a0vitro","volume":"1012","author":"Werner-Felmayer","year":"1989","journal-title":"Biochim. Biophys. Acta"},{"issue":"6","key":"10.1016\/j.neuropharm.2016.03.024_bib161","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/sj.mp.4001600","article-title":"IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity","volume":"10","author":"Wichers","year":"2005","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2016.03.024_bib162","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/978-1-4615-4709-9_19","article-title":"Degradation of tryptophan in neurodegenerative disorders","volume":"467","author":"Widner","year":"1999","journal-title":"Adv. Exp. Med. Biol."},{"issue":"3","key":"10.1016\/j.neuropharm.2016.03.024_bib163","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s007020050029","article-title":"Tryptophan degradation and immune activation in Alzheimer's disease","volume":"107","author":"Widner","year":"2000","journal-title":"J.\u00a0Neural Transm."},{"issue":"4","key":"10.1016\/j.neuropharm.2016.03.024_bib164","doi-asserted-by":"crossref","first-page":"e59749","DOI":"10.1371\/journal.pone.0059749","article-title":"Expression of tryptophan 2,3-dioxygenase and production of kynurenine pathway metabolites in triple transgenic mice and human Alzheimer's disease brain","volume":"8","author":"Wu","year":"2013","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.neuropharm.2016.03.024_bib165","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.steroids.2004.05.019","article-title":"Antigen-specific T cell functions are suppressed over the estrogen-dendritic cell-indoleamine 2,3-dioxygenase axis","volume":"69","author":"Xiao","year":"2004","journal-title":"Steroids"},{"issue":"17","key":"10.1016\/j.neuropharm.2016.03.024_bib166","doi-asserted-by":"crossref","first-page":"6622","DOI":"10.1073\/pnas.83.17.6622","article-title":"Interferon enhances tryptophan metabolism by inducing pulmonary indoleamine 2,3-dioxygenase: its possible occurrence in cancer patients","volume":"83","author":"Yasui","year":"1986","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.neuropharm.2016.03.024_bib167","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3233\/JAD-140414","article-title":"The IDO inhibitor coptisine ameliorates cognitive impairment in a mouse model of Alzheimer's disease","volume":"43","author":"Yu","year":"2015","journal-title":"J.\u00a0Alzheimers Dis."},{"issue":"4","key":"10.1016\/j.neuropharm.2016.03.024_bib168","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1582-4934.2010.01237.x","article-title":"Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines","volume":"15","author":"Zadori","year":"2011","journal-title":"J.\u00a0Cell Mol. Med."},{"issue":"1\u20132","key":"10.1016\/j.neuropharm.2016.03.024_bib169","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jns.2012.06.004","article-title":"Mitochondrial disturbances, excitotoxicity, neuroinflammation and kynurenines: novel therapeutic strategies for neurodegenerative disorders","volume":"322","author":"Zadori","year":"2012","journal-title":"J.\u00a0Neurol. Sci."},{"issue":"11","key":"10.1016\/j.neuropharm.2016.03.024_bib170","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1007\/s00702-009-0263-4","article-title":"Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies","volume":"116","author":"Zadori","year":"2009","journal-title":"J.\u00a0Neural Transm. (Vienna)"},{"issue":"6","key":"10.1016\/j.neuropharm.2016.03.024_bib171","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s00702-010-0573-6","article-title":"Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington's disease","volume":"118","author":"Zadori","year":"2011","journal-title":"J.\u00a0Neural Transm."},{"issue":"26","key":"10.1016\/j.neuropharm.2016.03.024_bib186","doi-asserted-by":"crossref","first-page":"24078","DOI":"10.1074\/jbc.M302051200","article-title":"Bicarbonate-dependent peroxidase activity of human Cu,Zn-superoxide dismutase induces covalent aggregation of protein: intermediacy of tryptophan-derived oxidation products","volume":"278","author":"Zhang","year":"2003","journal-title":"J. Biol. Chem"},{"issue":"16","key":"10.1016\/j.neuropharm.2016.03.024_bib172","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1093\/eurheartj\/ehs175","article-title":"The tryptophan metabolite 3-hydroxyanthranilic acid lowers plasma lipids and decreases atherosclerosis in hypercholesterolaemic mice","volume":"33","author":"Zhang","year":"2012","journal-title":"Eur. Heart J."},{"issue":"3","key":"10.1016\/j.neuropharm.2016.03.024_bib187","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1468-1331.2006.01575.x","article-title":"Riluzole and amyotrophic lateral sclerosis survival: a population-based study in southern Italy","volume":"14","author":"Zoccolella","year":"2007","journal-title":"Eur. J. Neurol"},{"issue":"6","key":"10.1016\/j.neuropharm.2016.03.024_bib173","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.cell.2011.05.020","article-title":"Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration","volume":"145","author":"Zwilling","year":"2011","journal-title":"Cell"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839081630096X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839081630096X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T01:52:19Z","timestamp":1718416339000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002839081630096X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":187,"alternative-id":["S002839081630096X"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2016.03.024","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2016.03.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}